Brief: Medmix Says Adjusted EBITDA Margin Guidance for FY 2023 Around 22% (Versus. 23%)
July 20 (Reuters) - medmix AG MEDX.S :
* FY 2023 GUIDANCE: 5-7% ORGANIC REVENUE GROWTH (N.C.),
ADJUSTED.
EBITDA MARGIN AROUND 22% (VERSUS. 23%)
* THROUGHOUT SECOND HALF, PROFITABILITY IS EXPECTED TO
IMPROVE
Source text for Eikon: ID:
Further company coverage: MEDX.S
((Reuters.Briefs@thomsonreuters.com;))